Zimmer will spin off says Bristol-Myers Squibb:
This article was originally published in Clinica
After some months of wavering between a sale or flotation for its Zimmer orthopaedics business, Bristol-Myers Squibb has decided on an IPO. Although both Swiss company Sulzer Medica and UK company Smith & Nephew announced interest, it was widely thought that the tax implications of a sale meant that a spin-off was the more attractive option. It is not yet known how much of Zimmer will be offered for sale or what value Bristol places on the company.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.
Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.